Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, and erlotinib, a small-molecule tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), are targeted agents approved in the treatment of NSCLC [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.